Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!